Concepedia

Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma

Pavlos Msaouel, Andrew L. Hong, Elizabeth A. Mullen, Michael B. Atkins, Cheryl L. Walker, Chung‐Han Lee, Marcus A. Carden, Giannicola Genovese, W. Marston Linehan, Priya Rao,

Clinical Genitourinary Cancer · 2018 · 96 citations · 30 references

DOIFull text

Open access

Concepts

References

30

The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia

John R. Srigley, Brett Delahunt, John N. Eble et al. · The American Journal of Surgical Pathology · 2013 · 1.1K citations

, , +16

Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2

Sarah K. Knutson, Natalie M. Warholic, Tim J. Wigle et al. · Proceedings of the National Academy of Sciences · 2013 · 782 citations · Full text

, , +16

Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study

Antoîne Italiano, Jean‐Charles Soria, Maud Toulmonde et al. · The Lancet Oncology · 2018 · 614 citations

, , +12

Renal Medullary Carcinoma The Seventh Sickle Cell Nephropathy

Charles J. Davis, F.K. Mostofi, Isabell A. Sesterhenn · The American Journal of Surgical Pathology · 1995 · 606 citations

, , +16

SMARCB1-mediated SWI/SNF complex function is essential for enhancer regulation

Xiaofeng Wang, Ryan S. Lee, B. Alver et al. · Nature Genetics · 2016 · 368 citations · Full text

, , +7